Featured Intelligence
The Feed
Hyperbaric Oxygen Has Thirteen Cleared Uses. Clinics Advertise Far More Than That
Hyperbaric oxygen therapy involves breathing pure oxygen inside a chamber pressurized above sea level, which forces far more oxygen into the blood plasma than normal breathing can. For a small set of conditions this is established medicine with a clear
Two Approved Cures for Sickle Cell, and Roughly Sixty People Treated
In December 2023 the FDA approved two gene therapies for sickle cell disease, one of them the first CRISPR-based medicine ever cleared anywhere. The disease affects around 100,000 people in the United States. More than two years later,
Freezing Ovarian Tissue to Postpone Menopause: What the Procedure Can and Cannot Do
A small number of healthy women have now banked slices of their own ovarian tissue, not because they are facing cancer treatment, but on the possibility of having it transplanted back in their forties to keep their ovaries producing hormones
Two Drugs Slow a Blinding Retinal Disease. Whether They Preserve Sight Is Still Open.
Geographic atrophy is the advanced dry form of age-related macular degeneration, in which patches of the retina's light-sensing layer die and expand until they reach the center of vision. Until recently there was nothing to offer.
An FDA Panel Backed Six Peptides for Compounding. Almost Nothing Legally Changed.
In July the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides that compounding pharmacies had nominated for the list of substances they are permitted to use. The panel recommended six of them: BPC-157, TB-500, KPV, MOTS-
Genomic Newborn Screening Is Past the Pilot Stage, and the Numbers Are More Interesting Than the Promise
The GUARDIAN study in New York has now enrolled 30,000 newborns, offering parents genome sequencing alongside the standard heel-prick screen every American baby already receives. The first published results covered 4,000 infants: sequencing flagged serious treatable conditions
Blood Grown in a Lab Has Now Been Transfused Into People. The Hard Part Is Scale.
A British trial called RESTORE has finished producing its final batch of laboratory-grown red blood cells, the last step before results are expected in late 2026 or early 2027. The study began transfusing manufactured cells into healthy volunteers in
The FDA Just Told an Exosome Seller Its Product Probably Contains No Exosomes
In August the FDA posted a warning letter to a network of companies selling injectable products derived from umbilical cord blood, Wharton's jelly and what the firms marketed as exosomes. The agency's findings covered the usual
The Isotope Problem: Why American Imaging and Cancer Therapy Depend on Aging Foreign Reactors
Tens of thousands of medical scans a day in the United States depend on a radioactive material with a 66-hour half-life that the country does not produce at commercial scale. Molybdenum-99 decays into technetium-99m, the workhorse
Join the Strategic Bio-Reserve
Institutional-grade intelligence on the next decade of biological power. Over 150,000+ experts securing the human code
